Motac Neuroscience

Motac Neuroscience is a United Kingdom-based contract research organisation (CRO) that specialises in preclinical proof-of-concept and efficacy studies for disorders of the central nervous system. According to its official website, the company provides highly specialised preclinical services to the pharmaceutical and biotechnology industries, supporting the discovery and development of therapeutics for neurological and psychiatric disorders. Its scientific focus centres on neurodegenerative conditions, particularly Parkinson's disease, as well as other movement and cognitive disorders. The company describes itself as offering world-class science and innovative technologies, with extensive expertise and research capabilities in neurodegeneration. It emphasises an unparalleled ability to provide access to the best available models of these conditions, underpinned by first-class scientific understanding and delivered in a commercial environment with an emphasis on quality and timeliness. Motac offers a wide range of in vivo and ex vivo services, including state-of-the-art model systems with translational validity, acute and progressive models of neurodegeneration, Parkinson's disease, drug-induced dyskinesias and cognitive performance. Beyond fee-for-service research, Motac holds an intellectual property portfolio protecting a number of new chemical entities and novel therapeutic targets for the treatment of movement disorders, which it develops through strategic alliances and partnerships. Its service menu includes models of proteinopathies such as Parkinson's disease, multiple system atrophy, Alzheimer's disease, progressive supranuclear palsy, Huntington's disease and amyotrophic lateral sclerosis; models of movement and cognitive disorders; models of spinal cord injury; stereotactic surgery; neurohistology and immunohistochemistry; neurochemistry and neurobiochemistry; in vivo chronic calcium imaging; and expert consultancy. The company is headquartered in Manchester, United Kingdom, and serves clients internationally across the pharmaceutical and biotechnology sectors.

Motac Neuroscience is a contract research organisation based in Manchester, United Kingdom, dedicated to preclinical research services for disorders of the central nervous system. The company was established to provide specialised preclinical proof-of-concept and efficacy studies to the pharmaceutical and biotechnology industries, supporting the discovery and development of therapeutics for neurological and psychiatric disorders. From its inception, Motac has focused on neurodegenerative conditions, particularly Parkinson's disease, and other movement and cognitive disorders. It has built extensive expertise and world-class research capabilities in these areas, offering access to state-of-the-art model systems with excellent translational validity. These include acute and progressive models of neurodegeneration, Parkinson's disease, drug-induced dyskinesias and cognitive performance. Over time, Motac has expanded its service offerings to cover a wide range of in vivo and ex vivo services. Its expertise now includes models of proteinopathies such as Parkinson's disease, multiple system atrophy, Alzheimer's disease, progressive supranuclear palsy, Huntington's disease and amyotrophic lateral sclerosis; models of movement disorders; models of cognitive disorders; models of spinal cord injury; stereotactic surgery; neurohistology and immunohistochemistry; neurochemistry and neurobiochemistry; and in vivo chronic calcium imaging. The company also provides expert consultancy on study design and execution. In addition to its service business, Motac has developed an intellectual property portfolio protecting a number of new chemical entities and novel therapeutic targets for the treatment of movement disorders. The company advances these assets through strategic alliances and partnerships, aiming to bridge the gap between preclinical and clinical research. Motac operates from its base in Manchester, United Kingdom, and serves a international clientele of pharmaceutical and biotechnology companies. Its commercial approach emphasises quality and timeliness, combining first-class scientific understanding with a customer-focused service model.

World-class science and innovative technologies in a commercial environment with an emphasis on quality and timeliness.

• Preclinical proof-of-concept and efficacy studies

  Tailor-made studies bridging the gap between preclinical and clinical research.

• In vivo and ex vivo services

  A wide range of highly-specialised services to support the preclinical development of new treatments for neurodegenerative disorders.

• Model systems

  State-of-the-art model systems with excellent translational validity, including acute and progressive models of neurodegeneration, Parkinson's disease, drug-induced dyskinesias and cognitive performance.

• Models of proteinopathies

  Models of PD, MSA, AD, PSP, HD and ALS.

• Stereotactic surgery

  Specialised surgical service for preclinical research.

• Neurohistology / Immunohistochemistry

  Histological and immunohistochemical analysis services.

• Neurochemistry / Neurobiochemistry

  Neurochemical and neurobiochemical analysis services.

• In vivo chronic calcium imaging

  Advanced imaging technique for chronic in vivo studies.

• Expert consultancy

  Expert advice on study design and execution.

1. 1Home - Motac Neurosciencemotac.com
2. 2Our Services - Motac Neurosciencemotac.com
3. 3Motac Neuroscience - Wikidatawikidata.org